TP53 (Tumor protein P53) • POLE (DNA Polymerase Epsilon) • CCNE1 (Cyclin E1) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • MUC16 (Mucin 16, Cell Surface Associated)

TP53 mutation

lunresertib (Debio2513) • camonsertib (RP-3500) • zedoresertib (Debio 0123)

13d

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=66, Terminated, Debiopharm International SA | Active, not recruiting --> Terminated; This trial was concluded for strategic reasons.

13 days ago

Trial termination

CCNE1 (Cyclin E1)

zedoresertib (Debio 0123)

15d

A Possibility of Synthetic Lethality: Wee1 Kinase as a Promising Treating Target for Cancer. (PubMed, Med Res Rev)

Wee1 is the fastest progressing member in clinical research, and its inhibitors such as AZD-1775 and ZN-c3 are under clinical evaluation. We further summarize design principles for targeted degradation of Wee1 and outline combination strategies grounded in synthetic lethality, and we curate recent preclinical and ongoing clinical advances with discussion of biomarker-guided enrollment and dosing schedules. By linking structural mechanisms to pharmacology and clinical placement, this review provides an actionable framework for next-generation Wee1-directed drug design and translation in oncology.

15 days ago

Review • Journal

TP53 (Tumor protein P53) • PKMYT1 (Protein Kinase Membrane Associated Tyrosine/Threonine 1)

adavosertib (AZD1775) • azenosertib (ZN-c3)

19d

Debio 0123, a WEE1 kinase inhibitor: Phase 1 results from dose escalation in patients with advanced solid tumors. (PubMed, Eur J Cancer)

Debio 0123 demonstrated a manageable toxicity profile, exhibited linear pharmacokinetics and showed target engagement at doses ≥200 mg. Given the response observed in a subset of this heavily pre-treated population, results support further investigation of Debio 0123 in selected indications.

19 days ago

P1 data • Journal

CDK1 (Cyclin-dependent kinase 1)

zedoresertib (Debio 0123)

19d

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC (clinicaltrials.gov)

P1/2, N=7, Terminated, Filipa Lynce, MD | N=78 --> 7 | Trial completion date: Sep 2029 --> Feb 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2027 --> Feb 2026; Zentalis terminated contract due to concern for toxicity safety from previously reported serious adverse events.

19 days ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD4 (CD4 Molecule)

HER-2 negative

Keytruda (pembrolizumab) • carboplatin • azenosertib (ZN-c3)

21d

In addition, high-risk patients exhibited significant enrichment in pathways related to TP53 dysfunction, mechanistic target of rapamycin complex 1 (mTORC1) signaling activation, and pro-inflammatory responses, which were closely correlated with NPM1c-FLT3 co-mutations. Decitabine, sunitinib, and MK-1775 were identified as potential therapeutic agents. In summary, we established a 5-ARG prognostic model that may facilitate risk stratification and inform therapeutic decision-making in AML.

21 days ago

Journal

TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • ENO1 (Enolase 1) • SLC7A11 (Solute Carrier Family 7 Member 11) • DDIT4 (DNA Damage Inducible Transcript 4) • HSP90AB1 (Heat Shock Protein 90 Alpha Family Class B Member 1)

NPM1 mutation

sunitinib • adavosertib (AZD1775) • decitabine • sirolimus

22d

ASPENOVA: A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression (clinicaltrials.gov)

P3, N=420, Recruiting, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | Not yet recruiting --> Recruiting

22 days ago

Enrollment open • Platinum resistant

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • CCNE1 (Cyclin E1) • BRCA (Breast cancer early onset)

BRCA2 mutation • BRCA1 mutation • BRCA mutation

paclitaxel • azenosertib (ZN-c3)

Debio 0123-SCLC-104: Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy (clinicaltrials.gov)

P1, N=34, Terminated, Debiopharm International SA | Active, not recruiting --> Terminated; The trial was concluded for strategic reasons.

1 month ago

Trial termination

carboplatin • etoposide IV • zedoresertib (Debio 0123)

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study (clinicaltrials.gov)

P1, N=13, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2026 --> Dec 2026

1 month ago

Trial completion date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • CD4 (CD4 Molecule)

BRCA2 mutation • BRCA1 mutation • BRIP1 mutation

Lynparza (olaparib) • adavosertib (AZD1775)

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers (clinicaltrials.gov)

P1, N=4, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2026

1 month ago

Trial completion date

adavosertib (AZD1775)

2ms

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2 (clinicaltrials.gov)

P2, N=18, Active, not recruiting, National Cancer Institute (NCI) | N=60 --> 18 | Trial completion date: Mar 2026 --> Apr 2027

2 months ago

Enrollment change • Trial completion date

SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase)

adavosertib (AZD1775)